…als (www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/statement-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html), it is unclear at present if all provinces will extend access to booster vaccines to MS patients. The U.S. National MS Society has made similar recommendations but includes siponimod and ponesimod and excludes cladribine from its lis…

…Neurol 2018;17:405-415). There was a 44% reduction in progression on the 9-Hole Peg Test (9HPT), but it was unclear if this was due to natalizumab’s effects on inflammatory disease activity. A new post-hoc analysis reported a significant effect of natalizumab on 6-month confirmed 9HPT progression in patients with no disease activity, including those with no relapses (odds ratio 0.56) and those with no new MRI lesions (OR 0.57). The treatment effe…

…384. The proportion reaching EDSS >6.0 confirmed at 24 weeks was 8.5%. Long-term data are not yet available for ofatumumab. Mathematical modelling of ASCLEPIOS data estimated that ofatumumab-treated patients would spend 66% of their time at EDSS <3.0 over the first 10 years of therapy. Overall, 11.3% of patients would progress to EDSS >7.0 with ofatumumab compared to 15.0% with teriflunomide at 10 years (Vudumula et al. ECTRIMS 2021; P913). COVID-…